# Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

> **NCT06296745** · PHASE2 · RECRUITING · sponsor: **Guangzhou Medical University** · enrollment: 36 (estimated)

## Conditions studied

- Leptomeningeal Metastasis

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT06296745
- **Lead sponsor:** Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-01-20
- **Final completion:** 2027-03-20
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06296745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06296745, "Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06296745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*